In a recent study, researchers from Baylor College of Medicine and Boston Children’s Hospital, among other institutions, genetically modified T cells to control two major life-threatening complications, graft-vs-host disease (GvHD) and cancerRead More…
Chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting CD19 has achieved surprising results in the treatment of malignant hematological tumors such as relapsed/refractory acute lymphoblastic leukemia (ALL). Clinical trial data show that theRead More…
Immunotherapy is currently a hot topic in the field of tumor treatment, and has shown excellent therapeutic effects in clinic. Among all kinds, adoptive T cell therapy is undoubtedly the most anticipated.Read More…
In a new study, researchers from Massachusetts General Hospital find that the interferon gamma receptor (IFNγR) signaling pathway is critical for glioblastoma susceptibility to CAR-T cell immunotherapy . The same phenomenon hasRead More…
CAR-T (chimeric-antigen receptor T-cell immunotherapy) has significant efficacy in the treatment of acute leukemia and non-Hodgkin’s lymphoma, and is considered to be one of the most promising tumor treatments. In recent years,Read More…
The detection and destruction of cancer cells by immune cells is the basis of all modern immunotherapies, including cancer vaccines, checkpoint blocking, and adoptive immune cell therapy (ACT). To achieve the productionRead More…
In this March, Bristol-Myers Squibb and Bluebird Bio announced that their CAR-T cell therapy idecabtagene vicleucel (Abecma) targeting B cell maturation antigen (BCMA) has been approved for the treatment of multiple myeloma,Read More…
Adoptive immunotherapy is a transformational therapy in hematology. One of the most representative adoptive immunotherapies is chimeric antigen receptor (CAR) T cell therapy. It expresses and synthesizes CAR on T cells byRead More…
Regulatory T cells (Tregs) is a small group of immune cells, which specifically inhibit excessive immune activation and maintain immune homeostasis. In the past two decades, the advances in genome editing andRead More…
Bristol-Myers Squibb (BMS) and bluebird bio announced that the Food and Drug Administration (FDA) has approved the marketing of Abecma (idecabtagene vicleucel), a chimeric antigen receptor T (CAR-T) cell immunotherapy targeting BRead More…